Havens Offers Insight on FDA Cannabidiol Hearing in CNBC and Other Outlets

Havens Offers Insight on FDA Cannabidiol Hearing in CNBC and Other Outlets
FDA Kicks Off Review Of CBD With 140 People Scheduled To Testify At First Public Hearing Friday
May 30, 2019
Angelico Lavita

On Friday, May 31, the Food and Drug Administration (FDA) held its first hearing regarding the cannabidiol (CBD) industry, featuring 140 industry officials to testify. Jonathan Havens, chair and co-chair of the Firm’s Food and Beverage and Cannabis Law Practices, is quoted in CNBC prior to the meetings’ beginning. 

"I think a lot of people are holding out what I consider somewhat false hope that we’ll come out of this hearing with all the answers to our burning questions," predicted Jonathan.

In an interview with NutraIngredients-USA, Jonathan commented on the complexity of the material scheduled for discussion.

"I think FDA is asking some tough questions that don't have easy answers. Such as, how can you be sure how much CBD a user is getting, when you don’t even know what products they are consuming that have CBD in them?"